Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2

• Published in: bioRxiv
• Main Authors: Shi, Guoli, Chiramel, Abhilash I, Li, Tiansheng, Lai, Kin Kui, Kenney, Adam D, Zani, Ashley, Eddy, Adrian, Majdoul, Saliha, Zhang, Lizhi, Dempsey, Tirhas, Beare, Paul A, Kar, Swagata, Yewdell, Jonathan W, Best, Sonja M, Yount, Jacob S, Compton, Alex A
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 30.08.2022; Cold Spring Harbor Laboratory
• Edition: 1.5
• Subjects: Cervix; Clinical trials; COVID-19; Epithelial cells; Immunity; Infections; Influenza; Influenza A; Interferon; Microbiology; Rapamycin; Respiratory tract; Severe acute respiratory syndrome coronavirus 2; TOR protein; Viruses; COVID-19; IFITM; rapalog; SARS-CoV-2; microautophagy; TFEB; mTOR inhibitor; coronavirus; interferon; membrane fusion; rapamycin

SARS-CoV-2 infection in immunocompromised individuals is associated with prolonged virus shedding and evolution of viral variants. Rapamycin and its analogs (rapalogs, including everolimus, temsirolimus, and ridaforolimus) are FDA-approved as mTOR inhibitors for the treatment of human diseases, incl...